Valuation: Colinz Laboratories Limited

Market Cap 112M 1.16M 1.02M 946K 870K 1.63M 1.66M 11.31M 4.41M 54.68M 4.35M 4.25M 190M P/E 2024
19.5x
P/E 2025 36.8x
Enterprise Value 63.01M 651K 572K 532K 489K 917K 933K 6.36M 2.48M 30.73M 2.44M 2.39M 107M EV / Sales 2024
0.43x
EV / Sales 2025 2.04x
Free-Float
31.44%
Yield 2024 *
-
Yield 2025 -
06-17 Annjana Dugar, Likhitta Dugar and Antariksh Dugar executed of Share Purchase Agreement to acquire an additional 34.56% stake in Colinz Laboratories Limited from Vijaya Mani for INR 43.5 million, CI
06-17 Annjana Dugar, Likhitta Dugar and Antariksh Dugar proposed to acquire an additional 26% stake in Colinz Laboratories Limited for INR 35.4 million. CI
05-25 Padam Dugar, Annjana Dugar, Likhitta Dugar and Antariksh Dugar acquired 15.01% stake in Colinz Laboratories Limited. CI
04-29 Colinz Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
01-24 Colinz Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
01-16 Hilsun Foods And Drugs Private Limited signed a letter of intent to acquire Factory Building, Factory Machinery, & Factory Land of Colinz Laboratories Limited for INR 40 million. CI
11-27 Colinz Laboratories Limited Appoints Falguni Kumawat as Company Secretary and Compliance Officer, with Effect from 1 December, 2025 CI
11-08 Colinz Laboratories Limited Announces of Demise Dr. Mani L.S., Founder Director, Company Secretary and Compliance Officer on 7 November 2025 CI
11-03 Colinz Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
25-07-31 Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
25-05-21 Colinz Laboratories Limited Appoints Swapnil Jayesh Madiyar as Additional Director, Effective from May 16, 2025 CI
25-05-16 Colinz Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
25-03-04 Colinz Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
1 day+0.57%
1 week+3.73%
Current month-2.80%
1 month+12.49%
3 months+72.64%
6 months+45.86%
Current year+50.94%
1 week 76.2
Extreme 76.2
84.45
1 month 63.18
Extreme 63.18
87.44
Current year 39.31
Extreme 39.31
87.91
1 year 36.11
Extreme 36.11
87.91
3 years 33.35
Extreme 33.35
88.7
5 years 15.55
Extreme 15.55
88.7
10 years 4.8
Extreme 4.8
88.7
Manager TitleAgeSince
Chief Executive Officer 73 -
Director of Finance/CFO - 2019-05-19
Compliance Officer - 2025-11-30
Director TitleAgeSince
Director/Board Member 73 1990-11-25
Director/Board Member 33 2024-08-07
Director/Board Member 76 2024-08-07
Change 5-day change 1-year change 3-year change Capi.($)
+0.57%+3.73%+64.83%+130.96% 2.09M
-0.06%+1.14%+15.53%+77.64% 48.31B
+2.61%+1.86%+61.76%+112.38% 35.33B
+2.56%+0.77%-3.92%+36.29% 11.85B
-0.28%-2.75%+14.51%+81.20% 11.64B
-0.37%-0.19%+36.83%+136.73% 8.99B
+1.44%+0.37%+48.76%-5.84% 6.93B
-0.77%-3.48%+13.66%+32.01% 6.72B
-0.38%-1.74%+2.44%+178.64% 6.43B
+1.60%-15.49%-29.66%+8.47% 5.66B
Average +0.73%-1.27%+22.47%+78.85% 14.19B
Weighted average by Cap. +0.94%-0.93%+25.82%+82.45%

Financials

2024 2025
Net sales 70.3M 726K 638K 593K 545K 1.02M 1.04M 7.09M 2.77M 34.29M 2.73M 2.67M 119M 65.28M 674K 593K 551K 507K 950K 967K 6.59M 2.57M 31.84M 2.53M 2.48M 110M
Net income 4.87M 50.26K 44.2K 41.06K 37.77K 70.82K 72.09K 491K 192K 2.37M 189K 185K 8.24M 4.97M 51.28K 45.1K 41.9K 38.53K 72.27K 73.56K 501K 195K 2.42M 193K 188K 8.4M
Net Debt -64.3M -664K -584K -543K -499K -936K -953K -6.49M -2.53M -31.36M -2.49M -2.44M -109M -49.09M -507K -446K -414K -381K -714K -727K -4.95M -1.93M -23.95M -1.9M -1.86M -83.07M
Logo Colinz Laboratories Limited
Colinz Laboratories Ltd. is an India-based company that is engaged in the manufacturing and marketing of pharmaceutical formulations, particularly in the gynecological sector. It is engaged in the manufacturing and marketing various allopathic, ayurvedic, and nutraceuticals pharmaceutical formulations in the dosage forms of tablets, capsules, liquid orals and ointments, among others. The company has specialized products for Gynecology, cardiology, gastroenterology, and others. Its oncology products include imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, and doxorubicin. Its Ayurvedic products include anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, appetite stimulating agents, and memory boosters. Its nutraceuticals products include spirulina tabs/caps, spirulina with vitamins & minerals, omega 3 fatty acid caps in softgel, codliver oil with vitamin caps in soft gel, collagen, and glucosamine & chondroitin tabs.
Employees
65
Date Price Change Volume
26-07-24 80.95 +0.57% 23
26-07-23 ₹80.49 +0.45% 394
26-07-22 ₹80.13 -2.28% 1,188
26-07-21 ₹82.00 +2.56% 1,910
26-07-20 ₹79.95 +2.45% 691
  1. Stock Market
  2. Stocks
  3. COLINZ6 Stock